Agenus Inc (AGEN)

NASDAQ
5.620
+0.040(+0.72%)
After Hours
5.560
-0.060(-1.068%)
- Real-time Data
  • Volume:
    1,373,903
  • Bid/Ask:
    5.560/5.630
  • Day's Range:
    5.490 - 5.640

AGEN Overview

Prev. Close
5.58
Day's Range
5.49-5.64
Revenue
84.76M
Open
5.57
52 wk Range
2.5-5.94
EPS
-1.02
Volume
1,373,903
Market Cap
1.25B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,909,231
P/E Ratio
-
Beta
1.3
1-Year Change
65.29%
Shares Outstanding
222,441,009
Next Earnings Date
Aug 12, 2021
What is your sentiment on Agenus Inc?
or
Market is currently closed. Voting is open during market hours.

Agenus Inc News

Agenus Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Agenus Inc Company Profile

Agenus Inc Company Profile

Employees
359

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Read More
  • Good to buy guys?
    0
    • https://ch.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/COMPANY-TALK-J-J-nbsp-41-Prozent-Plus-mit-Morphosys-Wirkstoff-33013409/
      0
      • why is this one dropping so much?  i know there are 15% short, but the prospects are phenomenal
        0
        • IM ON IT ..... It is going to the roof auuuurrrr
          0
          • in perfect condition/
            0
            • ??? Doesn't really make sense mate.
              0
            • gutaussehend jung I know. Its just a chart. But i hope their products will be good... approved..
              0
            • really to entry It worth ?
              0
          • thoughts?
            0
            • loading on drops for longs
              0
              • adding more stock on my porfolio
                0
                • time to buy
                  0
                  • 7062551455
                    0
                    • 52003
                      0
                      • 7062551455
                        0
                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.